HBME-1和CK19、Galectin-3在甲状腺乳头状癌中表达及诊断价值

目的:了解HBME-1、CK19和Galectin-3在甲状腺乳头状癌中的表达状态,并探讨这3种抗体所构成的不同组合的诊断价值.方法:采用免疫组化检测55例甲状腺乳头状癌、24例甲状腺腺瘤、20例结节性甲状腺肿和10例桥本甲状腺炎中HBME-1、CK19和Galectin-3的表达.结果:HBME-1、CK19和Galectin-3在甲状腺乳头状癌中的阳性表达率分别为96.4%、98.2%、94.5%;在甲状腺良性病变中的阳性表达率分别为20.4%、20.4%、22.2%;3种抗体在甲状腺乳头状癌和良性病变中的阳性表达均存在统计学差异.HBME-1联合CK19、Galectin-3检测在鉴别甲状腺乳头状癌与良性病变时的敏感性、特异性、诊断正确率、阳性预测值和阴性预测值分别为100%、96.9%、98.8%、98%、100%.结论:HBME-1联合CK19、Galectin-3所构成的免疫组化组合在甲状腺乳头状癌与良性病变的鉴别诊断中具有重要的诊断价值.

Expression of HBME-1,CK19 and Galectin-3 in papillary thyroid carcinoma and their diagnostic value

Objective:To investigate the usefulness of immunohistochemical expression and immunolocalization of a panel of papillary thyroid carcinoma markers including HBME-1,CK19 and Galectin-3. Methods:By immunochemical EnVision method, the expression of HBME-1,CK19 and Galectin-3 were detected in 55 cases of papillary thyroid carcinomas,24 follicular adenomas, 20 multinodular goiters and 10 Hashimoto's thyroiditis. Results:The rates of immuno-positive staining of HBME-1,CK19 and Galectin-3 in papillary thyroid carcinoma were 96.4%,98.2% and 94.5%, respectively, which were significantly higher than that of benign lesions(20.4%, 20.4% and 22.2%, respectively). No significant relationship was found among the expressions of HBME-1, CK19 and Galectin-3. The sensibility, specificity,positive predictive value, negative predictive value and accuracy rate of using HBME-1 combined with CK19, Galectin-3 in differentiation benign from papillary thyroid carcinoma were 100%, 96.9%, 98.8%, 98%, 100% respectively. Conclusion:An immunohistochemical panel consisting of HBME-1, CK19 and Galectin-3 can make a correct differential diagnosis between papillary thyroid carcinoma and its benign mimics.